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Abstract The cerebral deposition of 40-42 residue amyloid p 
protein (Ap) is a characteristic of Alzheimer’s disease. Cathepsin 
D is possibly involved in the intracellular clearance of AjYl 
(Hamazaki, H. (19%) FEBS L&t., in press). The present work 
shows that cathepsin D hydrolyzes wild-type Ab 20 times faster 
than a variant AD with a substitution at residue 21 from Ala to 
Gly. Since the substitution has been linked to familial 
Alzheimer’s disease and hereditary cerebral hemorrhage with 
amyloidosis (Hendriks et al. (1992) Nature Genet. 1, 218-221), 
the present observations suggest that the inefficient elimination 
of Afl by cathepsin D is capable of being one of causes of the 
amyloid fibrll formation. 
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1. Introduction 
The cerebral deposition of amyloid P-peptide (AP) is one of 
the hallmarks of Alzheimer’s disease [1,2]. The 40-42 residue 
AP is normally produced by proteolytic processing from p- 
amyloid precursor protein (PAPP), a 110-130 kDa type 1 
integral membrane glycoprotein. AP is secreted from many 
cells including neurons [3,4] but the overproduction of AP 
or the production of more aggregatable AP variants are likely 
to lead to the formation of neuritic plaques and vascular 
deposits in the brain microvessels [3]. 
The missense mutation at codon 692 in PAPP770 from Ala 
to Gly has been linked to either hereditary cerebral hemor- 
rhage with amyloidosis (HCHWA) or presenile dementia sim- 
ilar to familial Alzheimer’s disease (FAD) [5]. This mutation 
leads to generation of a variant AP, AP(Ala21Gly). Recently, 
it has been shown that this mutation causes increased produc- 
tion of AP in vitro, in which human kidney 293 cells that were 
stably transfected to express PAPP(Ala692Gly) produced in- 
creases in secretion of AP and decreases in secretion of 3-kDa 
AP-related peptides with Val” and PhezO at their NHz-termini 
[6]. One possible cause of the excessive secretion of AP in this 
mutant is supposed to be the decease in the intracellular deg- 
radation of the variant AP, although the responsible protein- 
ase(s) have not been identified. 
*Fax: (81) 0427-78-8441. 
Abbreviations: AP, amyloid P-peptide; PAPP, P-amyloid precursor 
protein; FAD, familial Alzheimer’s disease; HCHWA, hereditary 
cerebral hemorrhage with amyloidosis; HCHWA-D, hereditary 
cerebral hemorrhage with amyloidosis of the Dutch type; RP-HPLC, 
reverse-phase high-performance liquid chromatography; TFA, tri- 
fluoroacetic acid 
In the previous paper, we have shown that cathepsin D is a 
major proteinase in the brain that is able to eliminate full- 
length AP by hydrolyzing specifically between Phelg and PhezO 
[7]. The present work shows that cathepsin D hydrolyzes wild- 
type AP over 20 times faster than a variant AP related with 
HCHWA/FAD. The results suggest that inefficient degrada- 
tion of the variant AD by cathepsin D can be a cause of 
excessive generation of the amyloidogenic peptide in the 
case of HCHWA/FAD. 
2. Materials and methods 
APl_ss was purchased from American Peptide Co. (Sunnyvale, 
CA). A!3_2s(Ala21Gly) was synthesized by Biosynthesis Inc. (Lewis- 
ville, TX) and purified on RP-HPLC in our laboratory. AP12_2s, 
AP12_2s(Ala2lGly), and A!312_&Glu22Gln) were prepared using 
Fmoc-chemistry in our laboratory and purified on RP-HPLC. The 
purity of all synthetic peptides were above 98% on RP-HPLC. Ca- 
thepsin D was purified from rat brain as described previously [7]. 
A!3 was hydrolyzed at a substrate concentration of 50 PM with 0.12 
pg of cathepsin D in 20 ~1 of 0.1 M acetate buffer, pH 4.5, at 37°C. 
Hydrolyzed products were analyzed on RP-HPLC using an Inertsil 
3OOC8 column (4.6 X 100 mm, GL Science, Japan). Column was eluted 
with a 20 min-linear gradient of 040% acetonitrile in 0.05% TFA at a 
flow rate of 1 ml/min and fractions with UV absorbance at 215 nm 
were collected for peptide sequencing. Peptides were sequenced on an 
Applied Biosystems model-491 protein sequencing system. 
3. Results 
In this study, synthetic peptides of Afi which include Phelg- 
PhezO but are shorter than the full-length AP, AP1-42, were 
used as substrate to compare susceptibility to cathepsin D, 
since cathepsin D specifically cleaves AP between Phelg- 
Phe20 and the full-length AP is not suitable for RP-HPLC 
analysis due to low recovery from the column (Fig. 1). 
AP12_2s and APl-28 have partial sequences of the wild-type 
AP. AP12_2s(Ala21Gly) and APl_zs(Ala21Gly) have an amino 
acid substitution related with HCHWA/FAD [5], and 
AP12_28(Glu22Gln) has a sequence related with hereditary cer- 
ebral hemorrhage with amyloidosis of the Dutch type 
(HCHWA-D) [8]. 
In the previous work it has been shown that cathepsin D is 
able to hydrolyze full-length AP specifically between Phelg 
and Phe20 producing less-aggregatable fragments [7]. Since 
amino acid substitution at P2 or P3 position may affect the 
cleavage by cathepsin D, AP&zs, AP12_zs(Ala21Gly), and 
AP12_2s(Glu22Gln) were incubated with cathepsin D and sub- 
sequently hydrolyzed products were separated on RP-HPLC 
and sequenced (Fig. 2). Cathepsin D hydrolyzed all the sub- 
strates commonly between Phelg and Phe20, and no other 
cleavages were observed under the experimental conditions. 
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*h 2-28 VHHQKLVFFAEDVGSNK 
ApI _28(Ala21Gly) DAEFRHDSGYEVHHQKLVFFGEDVGSNK 
‘%2-28(*@1 GUY) VHHQKLVFFGEDVGSNK 
A& 2_28(GIU22Gh) VHHQKLVFFAQDVGSNK 
Fig. 1. Structure of Al3 used as substrate in this work. Substituted 
amino acids in Al3 variants related with HCHWA/FAD and 
HCHWA-D were highlighted. Arrow indicates the cleavage site by 
cathepsin D. 
However, the hydrolysis rate was very different; half of 
A131z_zs was hydrolyzed within 5 min, whereas it took over 
100 min to degrade half of APi2_ss(Ala21Gly) under the 
experimental conditions (Fig. 3). In contrast to 
APi2_ss(Ala21Gly), the hydrolysis rate of APis-zs(Glu22Gln) 
was almost identical with that of APiz_zs. The effects of sub- 
stitution at residue-21 on the susceptibility to cathepsin D 
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Fig. 2. Hydrolysis of APlz_zs, AP12~&+la21Gly), and APIz-as- 
(Glu22Gln) by cathepsin D. Substrate (1 nmol) was incubated 
with 0.12 pg of cathepsin D. Incubation times of Ap12-2s, 
AP12_2s(Ala21Gly), and AP12_2s(Glu22Gln) were 15 min, 150 min, 
and 15 min, respectively. 
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Fig. 3. Time course of hydrolysis of A&__28 and the variants by ca- 
thepsin D. Substrate (1 nmol) was incubated with 0.12 ug of cathep- 
sin D in 0.1 M acetate buffer, pH 4.5. 
Al3is_&Ala21Gly) (Fig. 4). The data indicate that the substi- 
tution at residue-21 from Ala to Gly made AP less susceptible 
to proteolysis by cathepsin D. 
4. Discussion 
The present data indicate that (1) cathepsin D hydrolyzes 
unsubstituted AP, AP(Ala21Gly), and AP(Glu22Gln) between 
Phelg and PhezO and (2) AP(Ala21Gly) is poorly hydrolyzed 
by cathepsin D as compared with unsubstituted Al3 and AP- 
(Glu22Gln). 
To date, six missense mutations of pAPP have been linked 
to cerebral hemorrhage with amyloidosis and Alzheimer’s dis- 
ease. Among them, two mutations lead to amino acid substi- 
tution within AP region. One is the mutation at codon 692 
from Ala to Gly in PAPPr70, which generates AP(Ala21Gly) 
and is linked to HCHWA/FAD [5]. The other is the mutation 
at codon 693 from Glu to Gln in 13APP7r0, which generates 
AP(Glu22Gln) and is linked to HCHWA-D [8]. Recently, it 
has been shown that cultured cells that were stably transfected 
to express PAPP(Ala692Gly) produced relative increases in 
secretion of AP and relative decreases in secretion of 3-kDa 
AD fragments [6]. Therefore, it seems plausible to suppose that 
the mutation linked to HCHWA/FAD produces the variant 
AD that is resistant to the intracellular clearance. In the case 
of HCHWA-D, the expression of the mutant pAPP in several 
lines of cells did not affect the amount of secreted Al3 [9-l 11. 
The amyloid fibril formation in HCHWA-D may be attribut- 
ed to the nature of the variant AP rather than to the amounts 
of secreted AD, since it has been demonstrated that the Aj3 
with a substitution at residue-22 from Glu to Gln is much 
easier to form amyloid fibril than the unsubstituted one [12]. 
Supposing that cathepsin D is involved in the intracellular 
clearance of AD, the results presented here are consistent 
with the observations in cultured cells [8-111. 
It has been shown that the human kidney 293 cultured cells 
double-transfected to overexpress both human /3APP and ca- 
thepsin D secreted much less A/3 than the control cells trans- 
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Fig. 4. Time course of hydrolysis of Al3_28 and Al3_&Ala21Gly) 
by cathepsin D. Substrate (1 nmol) was incubated with 0.12 ug of 
cathepsin D in 0.1 M acetate buffer, pH 4.5. 
fected to overexpress only human pAPP [ 131, suggesting that 
cathepsin D is involved in reducing the generation of AP in 
vivo. Although it has been described that cathepsin D was 
capable of producing the cleavages resulting in AJ3 generation, 
in which relatively short peptides were used as substrate 
[ 14,151, the previous work [7] and the studies using cultured 
cells [13] indicate that cathepsin D also contributes to reduc- 
tion of the aggregatable peptide. In conclusion, I propose that 
the substitution at codon 692 (Gly for Ala) in J3APPTm leads 
to produce a variant AP that is resistant to the clearance by 
315 
cathepsin D, which results in providing more precursors for 
aggregation. 
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